BAC
Bank of America Corporation
BAC has the edge over HIPO overall, supported by lower modeled downside and stronger modeled upside.
HIPO
Hippo Holdings Inc.
HIPO's outlook is improving, though it still trails on the overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
HIPO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| N/A | |
| N/A |
HIPO's revenue is currently strong, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIPO.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over HIPO in the historical PE scenario, which offers more potential upside but is not a forecast.
HIPO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.3x | $8.14 | -78% |
| Fair | 7.7x | $9.87 | -73% |
| Expensive | 11x | $14.71 | -60% |
| Forward | 23x | $36.96 | — |
| Current | 29x | $36.96 | — |
Historical ranges are pointers, not guarantees.
HIPO's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
HIPO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect HIPO to return to profit, with revenue growing.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over HIPO on earnings, with more consistent year-over-year improvement.
HIPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.58 | +23% |
| Q3 2026 | $1.29 | -65% |
| Q2 2026 | $4.73 | +$5.12 |
| Q1 2026 | $4.40 | +$6.48 |
| Q4 2025 | $2.22 | +$3.86 |
| Q3 2025 | $3.72 | +$8.89 |
| Q2 2025 | -$0.39 | +$6.68 |
| Q1 2025 | -$2.08 | +$7.96 |
| Q4 2024 | -$1.64 | +$9.94 |
HIPO earned $1.29 per share over the past year, down 65% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over HIPO on profitability, with a higher operating margin.
HIPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $156M | +29% |
| Q2 2026 | $144.7M | +23% |
| Q1 2026 | $121.5M | +10% |
| Q4 2025 | $120.4M | +18% |
| Q3 2025 | $120.6M | +26% |
| Q2 2025 | $117.3M | +31% |
| Q1 2025 | $110.3M | +30% |
| Q4 2024 | $101.9M | +58% |
HIPO has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -76 points |
| Q2 2026 | 7.6% | +4.2 points |
| Q1 2026 | 5.9% | +47 points |
| Q4 2025 | 5.7% | -41 points |
| Q3 2025 | 81% | +87 points |
| Q2 2025 | 3.4% | +44 points |
| Q1 2025 | -41% | -2.7 points |
| Q4 2024 | 46% | +107 points |
HIPO's operating margin was 5.7% last quarter, down 76 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
HIPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +330% |
| Q2 2026 | $43M | +73% |
| Q1 2026 | $8.4M | +$44.1M |
| Q4 2025 | $3.2M | +$9.7M |
| Q2 2025 | $24.8M | +$35.5M |
| Q1 2025 | -$35.7M | -303% |
| Q4 2024 | -$6.5M | +$42.4M |
| Q2 2024 | -$10.7M | +$27.6M |
HIPO has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over HIPO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
HIPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +478K shares |
| 1 year | +3.9% | +1M shares |
| 3 years | +14% | +3.3M shares |
| 5 years | +21% | +4.7M shares |
| Available history | +5479% | +26.5M shares |
HIPO has 27M diluted shares, up 3.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | $15.6M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $1.6M |
| Q1 2023 | $200,000 |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
HIPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -8.7x | Net Cash |
HIPO has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HIPO.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
HIPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 68.3 | Neutral |
HIPO's weekly RSI is 63 (neutral) and its Stochastic is 68 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over HIPO on valuation relative to its sector.
HIPO PE vs Financial Services Sector
| Metric | HIPO | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 13x | 120% above |
| PE % | 100 | 62 | 38 pts above |
HIPO is trading at 29x earnings, a 120% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
HIPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.9 | 6% above |
| 20 week MA | $32.7 | 13% above |
| 50 week MA | $29.9 | 24% above |
| 100 week MA | $29.4 | 26% above |
| 200 week MA | $22.6 | 63% above |
HIPO has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
HIPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $296.3 | $77.3 | -74% |
| 2022 | $77.3 | $12.1 | -84% |
| 2023 | $12.1 | $9.12 | -25% |
| 2024 | $9.12 | $27.4 | +200% |
| 2025 | $27.4 | $31.3 | +14% |
| 2026 YTD | $31.3 | $37.0 | +18% |
HIPO has the edge over BAC on returns for 2026, with the stronger performance.